

Take a look at our dissemination from 2020!

Acaster Lloyd Consulting had **36** publications in 2020, including:

14 manuscripts **18** posters and **4** oral presentations!

Our publications covered a variety of therapeutic and research areas...

...including **11** in Rare Diseases

Crossnohere N L, Fischer R, **Lloyd A J**, et al. Assessing the appropriateness of the EQ-5D for Duchenne muscular dystrophy: A patient-centered study. In Press at *Med Decis Making*. (2020)

Lloyd A J, Schofield H, Adlard N. Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued? *Curr Med Res Opin*. (2020)

Lo S H, Lachmann R, Williams A... **Lloyd A J**. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study, *Qual Life Res*. (2020)

Gallop K, Foerster D, Lawrence C...**Acaster S**. Estimation of Health Utilities for Non-Ambulatory Duchenne Muscular Dystrophy (DMD) Patients and Their Caregivers. *ISPOR EU*. Poster presentation. (Nov 2020)

Williams K, Buesch K, Piglowska N... **Acaster S**. The Development of a Conceptual Model on the Impact of Caring for an Individual with Nonsense Mutation Duchenne Muscular Dystrophy. *ISPOR EU*. Poster presentation. (Nov 2020)

Williams K, Buesch K, Piglowska N... **Acaster S**. Symptoms and Impacts of Nonsense Mutation Duchenne Muscular Dystrophy: A Qualitative Study and the Development of a Patient-Centred Conceptual Model. *ISPOR EU*. Poster presentation. (Nov 2020)

Williams K, Buesch K, Piglowska N, **Acaster S**. Symptoms and Impacts of Nonsense Mutation Duchenne Muscular Dystrophy at Different Stages of Ambulation. *ISPOR EU*. Poster presentation. (Nov 2020)

Lloyd A J, **Aggio D**, Slocomb T. Utilities for X-Linked Myotubular Myopathy (XLMTM) to Support Cost-effectiveness Modelling. *ISPOR EU*. Poster presentation. (Nov 2020)

Williams K, **Aggio D**, Chen, P... **Lloyd A J**, et al. Utility values associated with treatment attributes for atypical hemolytic uremic syndrome: a discrete choice experiment in five countries. *ISPOR EU*. Poster presentation. (Nov 2020)

Moderator: Drummond M. Panelists: Nicod E, **Lloyd A J**, Dent R. Do HTAs Need Special Approaches For Patient-Reported Outcomes in Rare Diseases? *ISPOR EU*. Issue panel. (Nov 2020)

Nafees B, **de Freitas H**, **Lloyd A J**, Olaye A, Pang F. A Societal Utility Study to Elicit Values for Stages of Metachromatic Leukodystrophy (MLD) in the United Kingdom. *ISPOR EU*. Poster presentation. (Nov 2020)

4 in Allergy

Acaster S, **Gallop K**, de Vries J, et al. Peanut allergy impact on productivity and quality of life (PAPRIQUA): Caregiver-reported psychosocial impact of peanut allergy on children. *Clin Exp Allergy*. (2020)

Acaster S, **Gallop K**, de Vries, J, et al. Psychosocial and productivity impact of caring for a child with peanut allergy. *Allergy Asthma Clin Immunol*, 16, 83. (2020)

DunnGalvin A, **Gallop K**, **Acaster S**, et al. APPEAL-2: A pan-European qualitative study to explore the burden of peanut-allergic children, teenagers and their caregivers. *Clin Exp Allergy*. (2020)

Couratier P, Montagne R, **Acaster S**, et al. Allergy to Peanuts imPacting Emotions And Life (APPEAL): the impact of peanut allergy on children, adolescents, adults and caregivers in France. *Allergy Asthma Clin Immunol*, 16, 86. (2020)



Take a look at our dissemination from 2020!

10 in Mental Health

Gerbas ME, Meltzer-Brody S, **Acaster S**, et al. Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making. *J Womens Health (Larchmt)*. (2020)

Gerbas M E, Eldar-Lissai A., **Acaster S**, et al. Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression. *Arch Womens Ment Health*, 23. (2020)

Mittal A, Huang M, Suthoff E, **Acaster S**, et al. Sustained Remission in a Double-Blind, Randomized, Placebo-Controlled Phase 3 trial of Zuranolone (SAGE-217) in Postpartum Depression. Poster presentation. *ASCP*. (May 2020)

Huang M, Deligiannidis KM, Suthoff E... **Acaster S**, et al. SAGE-217 in Postpartum Depression: Number Needed to Treat in a Phase 3, Randomized, Placebo-Controlled Trial. Poster presentation. *SOBP Annual Meeting*. (May 2020)

Mittal A, Deliginidias K, Huang M...**Acaster S**, et al. Effect of SAGE-217 on Anxiety Outcomes in Postpartum Depression in a Randomized, Placebo-Controlled Trial. Poster presentation. *SOBP Annual Meeting*. (May 2020)

Mittal A, Deligiannidis K, Huang M... **Acaster S**, et al. Evaluation of Insomnia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial of SAGE-217 in Postpartum Depression. Poster presentation. *SLEEP 2020, 34th Annual Meeting of the APSS*. (Jun 2020).

Deligiannidis KM, Huang M, Suthoff E... **Acaster S**, et al. Correlation of HAM-D and EPDS scores in a Phase 3 Trial of the Oral GABAAR Positive Allosteric Modulator SAGE-217 in Postpartum Depression. Poster presentation. *Psych Congress*. (Sept 2020)

Huang M, Deligiannidis KM, Suthoff E... **Acaster S**, et al. Edinburgh Postnatal Depression Scale (EPDS) Total Score Remission and Number Needed to Treat (NNT) Outcomes in a Phase 3, Placebo-Controlled Trial of Zuranolone in Postpartum Depression (PPD). Poster presentation. *Psych Congress*. (Sept 2020)

Deligiannidis KM, Werneburg B, Huang M...**Acaster S**, et al. Concurrent Improvement of Depressive and Anxiety Symptoms in Patients with Postpartum Depression Treated with the Oral Neuroactive Steroid Zuranolone. Poster presentation. *ACNP*. (Dec 2020)

Deligiannidis KM, Werneburg B, Huang M... **Acaster S**, et al. Clinical Global Impression Scale and Number Needed to Treat Outcomes in a Phase 3 Placebo-Controlled Trial of Zuranolone, a GABAA Receptor Positive Allosteric Modulator in Postpartum Depression. Poster presentation. *ACNP*. (Dec 2020)

6 Research methods

Verstraete J, **Lloyd A J**, Scott D, Jelsma J. How does the EQ-5D-Y Proxy version 1 perform in 3, 4 and 5-year-old children? *Health Qual Life Outcomes*. (2020)

Ara R, Hill H, **Lloyd A J**, Woods HB, Brazier J. Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory? *Value Health* (2020)

Dewilde S, Janssen B, **Lloyd A J**, Shah K. Exploration of the Reasons Why Health State Valuation Differs for Children Compared to Adults: A Mixed Methods Approach. Poster presentation. *ISPOR EU*. (Nov 2020)

Mukuria C, Rowen D, Brazier JE, McGarry L, Quittner A, Lou Y, Sosnay P, **Acaster S**. Comparison of the Psychometric Performance of a New Condition-Specific Preference-Based Measure Derived from the CFQ-R (CFQ-R-8D) to EQ-5D-3L and SF-6D to Evaluate Health-Related Quality-of Life (HRQOL) in People with Cystic Fibrosis (CF). Podium presentation. *ISPOR EU*. (Nov 2020)

Al-Janabi H, **Lloyd A J**, Remak E, Muszbek N. Carer Utilities in Cost-Utility Analyses (CUAs): Crucial Information or Additional Burden of Uncertainty? Workshop session. *ISPOR EU*. (Nov 2020)

Lloyd A J. Measuring children's health and HRQL with EQ-5D-Y: Values, scores and decisions. Oral presentation. *4th EuroQol Academy meeting*. [March 2020]



Take a look at our dissemination from 2020!

2 in Rheumatology

Williams K, Taylor PC, Dore RK... **Acaster S**. The evaluation of individual patient-level change in rheumatoid arthritis: do current estimates reflect a meaningful improvement for patients? Poster presentation. *ISOQOL*. (Oct 2020)

Taylor PC, Dore R, **Williams K**, **Acaster S**, et al. The interpretation of patient-reported outcomes in rheumatoid arthritis: do clinical trials adequately evaluate meaningful improvements for patients? Poster presentation. *ACR Convergence*. (Oct 2020)

2 in Oncology

Williams K, Gibson A, McNamara, ... **Lloyd A J**. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL). *J. Med. Econ*, 10. (2020)

Herdman M, Kerr C, Pavesi M, Garside J, **Lloyd A J**, Cubi-Molla P, Devlin N. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. *J Patient Rep Outcomes*, 4. (2020)

and 1 in Kidney Disease

Cooper J, **Lloyd A J**, Sanchez J J G, et al. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. *Health Qual Life Outcomes*. (2020)